What is BioLargo?
Founded in 1989 and headquartered in Westminster, BioLargo operates as a multifaceted technology innovator. The company specializes in developing and commercializing advanced solutions for waste water treatment, food processing, and medical disinfection. Its portfolio includes high-impact technologies such as the Advanced Oxidation System (AOS), CupriDyne, and the Isan system. Beyond industrial applications, BioLargo maintains a robust consumer-facing presence through its Odor-No-More and Deodorall product lines, which address moisture and odor control in both household and agricultural settings. This dual-track business model allows the firm to capture value from both large-scale infrastructure projects and high-margin consumer goods, positioning it as a versatile player in the environmental technology sector.
How much funding has BioLargo raised?
BioLargo has raised a total of $7.2M across 9 funding rounds:
Debt
$681K
Debt
$1.1M
Debt
$978K
Debt
$1.1M
Debt
$700K
Debt
$862K
Debt
$150K
Private Equity
$887K
Debt (2009): $681K, investors not publicly disclosed
Debt (2010): $1.1M, investors not publicly disclosed
Debt (2011): $978K, investors not publicly disclosed
Debt (2012): $1.1M, investors not publicly disclosed
Debt (2013): $700K, investors not publicly disclosed
Debt (2013): $862K, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Private Equity (2026): $887K, investors not publicly disclosed
Key Investors in BioLargo
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer specializing in late-stage private equity investments to support enterprise-level scaling and strategic market expansion.
Undisclosed Investor
A strategic debt provider focused on long-term capital structures for technology-driven industrial firms.
What's next for BioLargo?
With the successful closure of this major strategic investment, BioLargo is well-positioned to enhance its operational efficiency and market penetration. The company's strategic roadmap likely involves scaling the deployment of its AOS technology, which remains a cornerstone of its value proposition in the water treatment industry. Furthermore, the firm is expected to prioritize the commercialization of its medical and dental disinfection technologies, tapping into the growing demand for sustainable, high-efficacy sanitation solutions. By maintaining a disciplined approach to capital allocation, BioLargo aims to leverage its recent funding to drive sustainable revenue growth and long-term shareholder value, while continuing to refine its intellectual property pipeline to meet the evolving needs of the global industrial sector.
See full BioLargo company page
